Senores Pharmaceuticals Ltd. (IN:SENORES)
:SENORES
Want to see IN:SENORES full AI Analyst Report?
Top Page
Senores Pharmaceuticals Ltd.
(SENORES)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹1,194.00
▲(66.55% Upside)
Action:N/A
Date:05/24/26
The score is driven primarily by strong FY2026 reported growth and profitability, but meaningfully capped by persistent deeply negative free cash flow and weak cash conversion, which raise sustainability/funding-risk concerns. Technicals are supportive (price above key DMAs with positive MACD), while valuation looks relatively rich at a 28.18 P/E with no dividend yield data to offset.
Positive Factors
Strong FY2026 revenue and margins
FY2026's sharp revenue step-up to 6.33B with ~60% gross and ~18% net margin indicates meaningful scale and high-margin product economics. If sustained, these margins signal pricing power and operating leverage that can support durable cash earnings over months ahead.
Negative Factors
Deeply negative free cash flow
Persistently negative free cash flow (~-2.03B) despite reported profits implies heavy capex or working-capital drain. This is a structural funding risk: continued negative FCF can force debt/equity raises or constrain reinvestment, hurting long-term stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong FY2026 revenue and margins
FY2026's sharp revenue step-up to 6.33B with ~60% gross and ~18% net margin indicates meaningful scale and high-margin product economics. If sustained, these margins signal pricing power and operating leverage that can support durable cash earnings over months ahead.
Read all positive factors
Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)
Market Cap
₹51.14B
Dividend YieldN/A
Average Volume (3M)11.47K
Price to Earnings (P/E)24.3
Beta (1Y)0.91
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees194
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)6.54
Shares Outstanding46,053,590
10 Day Avg. Volume13,254
30 Day Avg. Volume11,469
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32
Revenue Forecast (FY)₹8.57B
Senores Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/ant...
Senores Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 2.52B | 6.33B | 3.83B |
| Gross Profit | 1.29B | 3.81B | 14.11M |
| EBITDA | 849.50M | 2.15B | 1.08B |
| Net Income | 502.10M | 1.15B | 6.85M |
Balance Sheet | |||
| Total Assets | 12.88B | 16.04B | 145.66M |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.32B | 3.85B |
| Total Debt | 2.41B | 3.42B | 3.15B |
| Total Liabilities | 4.54B | 6.39B | 50.70M |
| Stockholders Equity | 8.14B | 9.34B | 7.86B |
Cash Flow | |||
| Free Cash Flow | -2.27B | -2.03B | -2.03B |
| Operating Cash Flow | -280.86M | 620.50M | -459.20M |
| Investing Cash Flow | -3.34B | -1.21B | -4.29B |
| Financing Cash Flow | 4.39B | -13.30M | 5.73B |
Senores Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹16.72B | 36.38 | ― | ― | 41.76% | 71.38% | |
65 Neutral | ₹51.14B | 24.33 | ― | ― | ― | ― | |
65 Neutral | ₹1.38B | 111.96 | ― | ― | ― | ― | |
58 Neutral | ₹1.30B | 16.40 | ― | 1.62% | -2.02% | 29.14% | |
56 Neutral | ₹511.81M | 172.45 | ― | ― | -27.51% | 356.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹398.81M | -4.63 | ― | ― | -48.93% | -180.45% |
* Healthcare Sector Average
IN:SENORES
Senores Pharmaceuticals Ltd.
1,110.45
606.20
120.22%
IN:BALAXI
Balaxi Pharmaceuticals Limited
25.06
-27.92
-52.70%
IN:BALPHARMA
Bal Pharma Limited
81.96
-14.68
-15.19%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
31.45
-15.46
-32.96%
IN:LASA
Lasa Supergenerics Ltd.
7.96
-8.88
-52.73%
IN:SAKAR
Sakar Healthcare Ltd
761.60
452.50
146.39%
Senores Pharmaceuticals Ltd. Corporate Events
Senores Pharmaceuticals Files Annual SEBI Disclosure on Promoter Share Encumbrances
Apr 22, 2026
Senores Pharmaceuticals has informed Indian stock exchanges that it has submitted its annual disclosure under Regulation 31(4) of the SEBI Substantial Acquisition of Shares and Takeovers framework. The filing details encumbrances on company shares...
Senores Pharmaceuticals Approves ₹95 Crore Preferential Warrant Allotment
Mar 28, 2026
Senores Pharmaceuticals’ board has approved the allotment of 1,170,000 fully convertible warrants on a preferential basis, each exchangeable for one equity share at an exercise price of ₹812, for a total potential raise of about ₹...
Senores Pharmaceuticals Allots ₹95 Crore in Convertible Warrants on Preferential Basis
Mar 28, 2026
Senores Pharmaceuticals has approved the allotment of 1,170,000 convertible equity warrants on a preferential basis, each entitling the holder to subscribe to one equity share at an exercise price of ₹812. The issue, which has received requi...
Senores Pharmaceuticals Closes Trading Window Ahead of FY 2026 Results
Mar 27, 2026
Senores Pharmaceuticals Ltd. has announced the closure of its trading window for company securities for directors, promoters, designated persons and their immediate relatives from April 1, 2026, in line with SEBI’s Prohibition of Insider Tra...
Senores Pharma Overhauls Senior Management as CTO Elevated, R&D Head Resigns
Mar 17, 2026
Senores Pharmaceuticals Ltd. has reshuffled its senior management, with the board approving the categorization of Chief Technology Officer Jatin Gajjar as Senior Management Personnel, effective March 17, 2026. Gajjar brings over three decades of e...
Senores Pharma Reshapes Senior Ranks as CTO Joins Top Management, R&D Head Exits
Mar 17, 2026
Senores Pharmaceuticals has reshaped its senior management structure by designating Chief Technology Officer Jatin Gajjar as Senior Management Personnel, effective March 17, 2026, following board approval based on the nomination and remuneration c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.